Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.98 and traded as high as $3.23. Sonoma Pharmaceuticals shares last traded at $3.16, with a volume of 84,647 shares changing hands.

Sonoma Pharmaceuticals Stock Up 7.8 %

The firm’s 50-day moving average price is $2.39 and its 200 day moving average price is $0.98.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The firm had revenue of $3.39 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 35.91% and a negative return on equity of 65.66%. Sell-side analysts predict that Sonoma Pharmaceuticals, Inc. will post -4 earnings per share for the current fiscal year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.